ENDO-205 First Non-Hormonal Targeted Peptide for Endometriosis — FDA IND Approval. New Option for 190 Million Reproductive-Age Women

The possibility of breaking from 30 years of hormone-suppression endometriosis treatment lines has opened. EndoCyclic’s ENDO-205 received US FDA IND (Investigational New Drug) approval in AprilMay 2026 and entered phase 1 human trials. As the first non-hormonal·lesion-targeted peptide endometriosis treatment, it has potential to avoid the menopause-like side effects·bone loss of existing hormone suppression (GnRH agonist·danazol) lines. A direct response to the 710 year average diagnostic delay gap of this disease affecting ~10% (190 million) of reproductive-age women.

What Is Endometriosis

Endometriosis is a disease where endometrial tissue lining the inside of the uterus grows outside (ovaries·peritoneal cavity·intestine·peritoneum·rarely lung·brain). It bleeds with each menstrual cycle but has no exit, causing chronic inflammation·adhesions·pain.

Symptoms:

• Chronic pelvic pain (worst during menstruation)
• Menstrual pain (progressive worsening)
• Dyspareunia (pain during intercourse)
• Pain during defecation·urination
• Chronic fatigue
• Infertility (30~50% of patients)

Patient statistics:

• Globally ~10% of reproductive-age women (190 million)
• Korea ~500,000 (likely under-diagnosed)
• Average diagnosis age: early 30s
• Average diagnostic delay: 7~10 years (from symptom onset to formal diagnosis)

Limitations of Existing Standard Treatment

All endometriosis standard treatments are hormone suppression lines:

1. Oral contraceptives (low-dose):

• Menstrual bleeding ↓ → pain relief
• Side effects: thrombosis·depression·weight changes
• Must stop for pregnancy planning

2. Progestin monotherapy:

• Dienogest (Visanne etc)
• Endometrial atrophy
• Side effects: bleeding pattern changes·depression·weight gain

3. GnRH agonist (Lupron·Zoladex etc):

• Pituitary-ovarian axis blockade → artificial menopausal state
• Strong effect
• Side effects: hot flashes·bone loss (average 6% in 6-month use)·insomnia·depression
• No continuous use over 6 months

4. GnRH antagonist (elagolix·relugolix):

• Faster acting·oral
• Slightly fewer side effects than GnRH agonist
• Still hormone suppression line

5. Laparoscopic surgery:

• Lesion removal + adhesiolysis
• Good efficacy
• 5-year recurrence 30~50%

The biggest gap — no drug that directly targets lesions without touching hormones.

What Makes ENDO-205 Different

Non-hormonal peptide:

• Targets specific receptor expressed on endometriosis lesions
• Doesn’t touch hormone systems (estrogen·progesterone)
• Preserves normal endometrium, attacks only ectopic endometriotic tissue

Mechanism (per EndoCyclic announcement):

1. Bind receptor overexpressed on endometriotic lesions
2. Block signal transduction → lesion atrophy
3. Simultaneously block inflammation·neural signaling → pain relief

Phase 1 Study Design

Primary endpoint: safety·pharmacokinetics (PK) Secondary: pain score·lesion size change signals Subjects: endometriosis patients with insufficient standard treatment Duration: 1218 months recruitment·observation Size: first phase 1 estimated 3050 patients Expected completion: late 2027 (phase 2 in 2028~2029)

Fertility Preservation Is Central

The biggest limit of existing hormone lines — must stop drug for pregnancy planning:

• GnRH agonist: cannot conceive while using
• Oral contraceptives·progestins: stop for pregnancy
• Symptoms·pain rebound quickly when drug stopped

ENDO-205 potential:

• Doesn’t touch hormones → pregnancy possibility preserved
• Decisive meaning for reproductive-age patients
• However, pregnancy data needs separate validation after phase 1~3 data accumulation

Endometriosis 7~10 Year Diagnostic Delay

Why diagnosis is late:

• Social perception that “menstrual pain is normal”
• Lack of physician awareness (especially primary care)
• Definitive diagnosis is laparoscopic surgery (invasive)
• MRI·ultrasound are auxiliary tools
• Symptom diversity (menstrual pain·chronic pelvic pain·GI symptoms confused)

Recent diagnostic tool changes:

• Non-invasive MRI precision evaluation (3T MRI, gadolinium contrast)
• Blood biomarker research (BCL6, miRNA panels etc)
• AI-based symptom analysis tools

Natural Matrix — Endometriosis Adjunct

Beside drug matrices like ENDO-205, natural matrix matters too:

Diet:

• Anti-inflammatory diet (omega-3·olive oil·green vegetables)
• Try gluten·dairy avoidance (effective in some patients)
• Cruciferous vegetables (broccoli·cauliflower): estrogen metabolism stabilization
• Fiber 25~35 g/day (estrobolome normalization)

Supplements:

• Omega-3 EPA/DHA 1~2 g/day
• Vitamin D 2,000~5,000 IU/day
• Magnesium 300~400 mg/day (muscle·pain)
• Curcumin (anti-inflammatory)
• NAC (N-acetylcysteine): some RCTs show pain ↓

Lifestyle:

• Exercise (endometriosis risk ↓)
• Chronic stress management
• Avoid environmental hormones (BPA·phthalates)
• Adequate sleep

Drug Matrix — Stage-Based Options

Mild (menstrual pain primary):

• NSAIDs (ibuprofen·naproxen)
• Low-dose oral contraceptives
• Natural matrix

Moderate (chronic pelvic pain):

• Dienogest (Visanne)
• Elagolix (Orilissa)
• Adjunct pain management

Severe (organ involvement·infertility):

• Laparoscopic surgery
• GnRH agonist (short-term)
• Future ENDO-205 (if FDA approved)
• Pregnancy planning integrated management

Korean Clinical Significance

Korean endometriosis statistics:

• ~500,000 estimated (likely underdiagnosed)
• ~50,000 new diagnoses annually
• Average diagnostic delay 57 years (shorter than US·Europe)
• Cost coverage: all standard treatments covered, dienogest applies specialty disease cost reimbursement

Korean clinical landscape:

• Increasing OBGYN·endometriosis specialty clinics
• Laparoscopic surgery normalized
• New drugs like ENDO-205 expected to take 5~7 years for Korean introduction

Conclusion

ENDO-205 is a candidate drug breaking the first crack in 30 years of endometriosis hormone-suppression standard. FDA IND approval is just the start — phase 13 to market introduction takes 57 years. But the meaning is clear — the first option enabling fertility preservation + hormone side-effect avoidance + lesion targeting simultaneously. A new ladder for chronic pain·diagnostic delay·pregnancy conflict management for 190 million women. Existing drug matrix + natural matrix + future drug lines integrating.